Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22988249 | 0.82 | NR1H2 (0.32) | ADORA2AADORA3ADORA1NR1H2NR1H3 | |
| SCHEMBL22987708 | 0.81 | NR1H2 (0.48) | ADORA2AADORA3ADORA1NR1H2NR1H3 | |
| SCHEMBL29646424 | 0.81 | ADORA3 (0.38) | ADORA2AADORA3ADORA1P2RX7NR1H2 | |
| SCHEMBL22987632 | 0.81 | ADORA3 (0.40) | ADORA2AADORA3ADORA1NR1H2NR1H3 | |
| SCHEMBL22978982 | 0.81 | ADORA3 (0.38) | ADORA2AADORA3ADORA1P2RX7NR1H2 | |
| SCHEMBL22987510 | 0.80 | NR1H2 (0.50) | ADORA2AADORA3ADORA1NR1H2NR1H3 | |
| SCHEMBL22988222 | 0.80 | ALDH1A1 (0.35) | ADORA2AADORA3ADORA1NR1H2NR1H3 | |
| SCHEMBL22988026 | 0.80 | HTT (0.35) | ADORA2AADORA3ADORA1NR1H2NR1H3 | |
| SCHEMBL22987505 | 0.78 | NR1H2 (0.41) | NR1H2NR1H3ALDH1A1 | |
| SCHEMBL22988072 | 0.78 | ADORA3 (0.33) | ADORA2AADORA3ADORA1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | ADORA2A 103/4885ADORA3 34/4885ADORA1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.